Medical studies link xanthelasma and atrial fibrillation to cardiovascular risks

Recent medical research has highlighted new ways to assess cardiovascular and stroke risks. The SINGLE AF trial, published in the New England Journal of Medicine, addresses the complexities of treating patients with atrial fibrillation who fall into an intermediate risk category. While current guidelines often suggest oral anticoagulants as a reasonable option (Class IIa), the study emphasizes the need for personalized clinical decisions to balance stroke prevention against bleeding risks.

Separately, a study published in the journal Atherosclerosis by researchers at Stanford University investigated the link between xanthelasma—yellowish deposits around the eyes—and major adverse cardiovascular and cerebrovascular events (MACCE). Analyzing data from nearly 18,000 individuals, researchers found that patients with xanthelasma faced significantly higher rates of heart attack, stroke, and transient ischemic attacks (TIA) compared to control groups over a 10-year period. These lipid accumulations may serve as visible indicators of underlying atherosclerosis.